HUDDINGE, Sweden, April 27, 2023 /PRNewswire/ — “Thanks to the strong interest from clinicians and patients, we were able to swiftly dose the first patients in the phase 2a part of the combination study with fostrox and Lenvima® in HCC after completed dose escalation” January – March…